L.A. Care, the nation's largest publicly operated health plan, was fined $55 million for failing to authorize care thousands of poor and at-risk members, causing health-threatening treatment delays.
B. Braun Medical recalled five lots of leaky 250 milliliter sodium chloride injections, the latest in a string of supply disruptions.
The nursing home industry is leading a drive across several states to regulate nurse staffing agencies, including urging lawmakers to cap rates.
Microsoft has officially purchased AI company Nuance Communications, in a deal the company said will accelerate its cloud strategy in industries including healthcare.
The Senate narrowly passed a resolution that would end the COVID-19 national emergency, but it is unlikely to pass the House.
New guidance from CMS also recommends states process no more than one-ninth of renewals per month.
A top Sutter Health finance executive said during testimony in a federal trial that her organization is not required to provide free or discounted care, otherwise known as charity care, as a condition of being not-for-profit. Experts say that's true, with caveats.
The Senate narrowly passed a resolution that would end the public health emergency, but it is unlikely to pass the House.
The pharmaceutical company is attempting to lower the cost of the drug for consumers to $30 per vial of insulin and $55 for a box of five pen cartridges.
Purdue Pharma reached a settlement Thursday over its role in the nation’s deadly opioid crisis that includes U.S. states and thousands of local governments.
Marginalized communities lose healthcare access as New York moves to close facilities and cut costs.
Nursing home resident advocates and those in charge of the facilities are at odds over industry reforms President Joe Biden announced during the State of the Union address.
Investors accuse the insurtech of hiding a federal criminal investigation and engaging in unlawful business practices.
By participating in GPDC, CareAllies aims to expand its geographic footprint in Texas and Arizona.
Pfizer’s new treatment came with a catch when it debuted late last year: Supplies were limited, and it can take months to make the tablets.
Fewer than one-third of complaints filed ended up being investigated by the Department of Consumer and Worker Protection.
